Floatz Rating
B62/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00126503CT.gov Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | — | Completed | — | — | — |
NCT00098618CT.gov Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Papillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | National Cancer Institute (NCI) | P2 | B · 62 |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | First Affiliated Hospital, Sun Yat-Sen University | P3 | BB |
| Pembrolizumab | First Affiliated Hospital, Sun Yat-Sen University | P3 | BB |
| Cabozantinib | National Cancer Institute (NCI) | P2 | BB |
| Volitinib | AstraZeneca | P3 | BB |
| Durvalumab | AstraZeneca | P3 | B |
| Crizotinib | National Cancer Institute (NCI) | P2 | B |
| Everolimus | Novartis Pharmaceuticals | P2 | B |
+27 more in the Papillary Renal Cell Carcinoma cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Papillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-papillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →